Vaxcyte COO Sells $435K in Shares

Jim Wassil reduces stake by 4.24% as Vaxcyte stock trades near $56

Mar. 12, 2026 at 2:04pm

Got story updates? Submit your updates here. ›

Vaxcyte, Inc. (NASDAQ:PCVX) Chief Operating Officer Jim Wassil sold 7,395 shares of the company's stock on March 10 at an average price of $58.88, generating $435,417.60. The sale reduced Wassil's stake in Vaxcyte by 4.24% to 166,818 shares valued at around $9.82 million. Vaxcyte, a clinical-stage biotech focused on developing preventive vaccines, recently reported quarterly earnings that missed analyst estimates.

Why it matters

Insider transactions, especially by C-suite executives, can provide insights into a company's performance and future prospects. Wassil's sale, while relatively small, may signal some uncertainty about Vaxcyte's near-term outlook following its earnings miss. However, the company maintains a strong institutional investor base and positive analyst sentiment, suggesting long-term confidence in its vaccine pipeline.

The details

Vaxcyte reported quarterly earnings on February 24, with EPS of ($1.80) missing the ($1.46) estimate. The company's stock trades near $56.56 with a market cap of $8.14 billion and a 52-week range of $27.66 to $76.61. Institutional ownership is around 96.78%, with major increases from investors like T. Rowe Price, Adage Capital, and Polar Capital. Analysts maintain a "Moderate Buy" consensus rating on Vaxcyte with a $94.50 price target.

  • The share sale occurred on March 10, 2026.

The players

Jim Wassil

The Chief Operating Officer of Vaxcyte, Inc.

Vaxcyte, Inc.

A clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Insider transactions can provide insights into a company's performance, but Vaxcyte's strong institutional backing and positive analyst sentiment suggest the COO's relatively small sale may not be a major concern. The company's focus on developing innovative preventive vaccines continues to garner investor interest despite near-term earnings challenges.